Benzinga | Jan 20, 2021 06:02AM EST

Aptorum Group Receives Health Canada Clearance To Initiate Phase 1 Clinical Trial For ALS-4, A Small Molecule Drug For Infections Caused By Staphylococcus Aureus including MRSA

Aptorum Group Limited (NASDAQ:APM, Euronext Paris: APM))))) ) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced that the company, through its wholly owned subsidiary, Aptorum International Limited, has received clearance from the Public Health Agency of Canada (Health Canada) regarding the Clinical Trial Application (CTA) to commence a Phase 1 study of ALS-4, an orally administered small molecule drug intended to treat infections caused by Staphylococcus aureus including MRSA.